A complete application in a minute
Tailored resume and cover letter, ready to send.
Nona Biosciences, based in the Bay Area, seeks a seasoned Biotech BD professional to drive new business with preclinical CRO partners and biotech startups. You will translate scientific capabilities into compelling value propositions and cultivate long-term relationships with key customers across the U.S.
This role requires 8+ years in sales or business development, a Master’s degree, and strong networking and negotiation skills.
Nona Biosciences is a global biotechnology company committed to providing a total solution for partners worldwide, from academies, biotech startups to biopharma giants. The integrated antibody discovery services range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging the advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team.
Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs by diversified partnership strategies. The values of the antibody discovery platforms and flexible partnership models have been well validated.
https://www.nonabio.com/en/Index.html
We are a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases.
Our discovery and development programs are driven by unmet medical and patient needs and strong science supported by our two patented transgenic mouse platforms for generating fully human monoclonal antibodies. We focus on developing an innovative pipeline of Next-Gen therapeutics through our internal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.
With operations in the US, the Netherlands, and China, we also license our core platform technology to other companies and academic institutions globally. We are a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases.
Our discovery and development programs are driven by unmet medical and patient needs and strong science supported by our two patented transgenic mouse platforms for generating fully human monoclonal antibodies. We focus on developing an innovative pipeline of Next-Gen therapeutics through our internal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.
With operations in the US, the Netherlands, and China, we also license our core platform technology to other companies and academic institutions globally.
Our discovery and development programs are driven by unmet medical and patient needs and strong science supported by our two patented transgenic mouse platforms for generating fully human monoclonal antibodies. We focus on developing an innovative pipeline of Next-Gen therapeutics through our internal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.
With operations in the US, the Netherlands, and China, we also license our core platform technology to other companies and academic institutions globally.